◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Kilitch Drugs (India) Limited (KILITCH) Financial History

Name: Kilitch Drugs (India) Limited (KILITCH) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Kilitch Drugs (India) Limited (KILITCH) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 236 employees. Its market capitalization is roughly ₹7 billion. In the fiscal year ended 2026-03-31, KILITCH reported ₹2.4B in revenue and ₹302M in net income.

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally.

Interactive charts & full statements →

KILITCH Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹2.4B	₹2.0B	₹1.5B	₹1.4B	—
Gross Profit	₹1.1B	₹905M	₹731M	₹617M	—
Operating Income (EBIT)	₹342M	₹286M	₹211M	₹144M	—
Net Income	₹302M	₹267M	₹146M	₹104M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KILITCH Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹449M	₹896M	₹538M	₹489M	₹431M
Gross Profit	₹212M	₹454M	₹229M	₹226M	₹177M
Operating Income (EBIT)	₹18M	₹212M	₹52M	₹42M	₹24M
Net Income	₹29M	₹145M	₹44M	₹82M	₹30M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KILITCH Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	—	—	—	—	(₹12M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KILITCH Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹4.6B	₹3.1B	₹2.4B	₹2.2B	—
Total Liabilities	₹1.8B	₹1.1B	₹644M	₹689M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KILITCH viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

BAFNAPH · Bafna Pharmaceuticals Limited — ₹8 billion
AMANTA · Amanta Healthcare Limited — ₹7 billion
ZIMLAB · ZIM Laboratories Limited — ₹7 billion
VALIANTLAB · Valiant Laboratories Limited — ₹7 billion
0460 · Sihuan Pharmaceutical Holdings Group Ltd. — HK$7 billion
6185 · CanSino Biologics Inc. — HK$7 billion
0570 · China Traditional Chinese Medicine Holdings Co. Limited — HK$6 billion
4539 · Nippon Chemiphar Co., Ltd. — JPY 6 billion

← KIE All “K” companies KIM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.